Patent intelligence · US
US 11891389
PGDH inhibitors and methods of making and using
PGDH inhibitors and methods of making and using
Patent details — US 11891389
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 6, 2024
- Expiration
- Feb 1, 2044
- Applicant
- Myoforte Therapeutics, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/4184, A61K31/437, A61K31/4453
Quick answer
US 11891389 (PGDH inhibitors and methods of making and using) is held by Myoforte Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Myoforte Therapeutics, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/4184, A61K31/437, A61K31/4453, A61K31/454, A61K31/4545
More from Myoforte Therapeutics, Inc.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 11891389?
US 11891389 (PGDH inhibitors and methods of making and using) is held by Myoforte Therapeutics, Inc.. Status: granted. Granted Feb 6, 2024. Expires Feb 1, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11891389?
Myoforte Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 3 pharmaceutical patents for this assignee.
When does US 11891389 expire?
Our index shows an expiration date of Feb 1, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.